The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00764881




Registration number
NCT00764881
Ethics application status
Date submitted
1/10/2008
Date registered
2/10/2008
Date last updated
30/12/2014

Titles & IDs
Public title
Effects of SH T00658ID on Libido
Scientific title
Multi-center, Double-blind, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive Containing Estradiol Valerate and Dienogest (SH T00658ID) Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon) Over 6 Treatment Cycles on Alleviating Complaints of Reduced Libido in Women With Acquired Female Sexual Dysfunction (FSD) Associated With Oral Contraceptive Use
Secondary ID [1] 0 0
2008-002263-13
Secondary ID [2] 0 0
91548
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Contraception 0 0
Libido 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Treatment: Drugs - Microgynon
Treatment: Drugs - Placebo

Experimental: EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID) - Daily oral administration of one capsule BAY86-5027 [estradiol valerate (EV) / dienogest (DNG)] for 28 days per cycle in the sequential 4-phasic regimen for 6 treatment cycles.

Active Comparator: EE/LNG (Microgynon) + Placebo - Daily oral administration of one capsule ethinylestradiol (EE) / levonorgestrel (LNG) for 21 days, followed by 1 capsule placebo for 7 days (28 days total per cycle) for 6 treatment cycles.


Treatment: Drugs: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose

Treatment: Drugs: Microgynon
Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.

Treatment: Drugs: Placebo
Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS) - Change from Baseline FSFI domains in desire and arousal component scores at Cycle 6. The change in score ranges from -28 (worst) to 28 (best).
Timepoint [1] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Primary outcome [2] 0 0
Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Per Protocol Set (PPS) - Change from Baseline FSFI domains in desire and arousal component scores at Cycle 6. The change in score ranges from -28 (worst) to 28 (best).
Timepoint [2] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [1] 0 0
The Mean Absolute Values of FSFI Domain Score (Desire) at Baseline - Sum of questions 1 and 2 on sexual desire on the FSFI Questionnaire at Baseline. The normalized score for those 2 questions ranges from 1.2 (worst) to 6 (best).
Timepoint [1] 0 0
At Baseline
Secondary outcome [2] 0 0
The Mean Absolute Values of FSFI Domain Score (Desire) at Cycle 6 - Sum of questions 1 and 2 on sexual desire on the FSFI Questionnaire at Cycle 6. The normalized score for those 2 questions ranges from 1.2 (worst) to 6 (best).
Timepoint [2] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [3] 0 0
Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Desire) - Mean change from Baseline to Cycle 6 in the sum of questions 1 and 2 on sexual desire on the FSFI Questionnaire. The change in the normalized score for those 2 questions ranges from -4.8 (worst) to 4.8 (best).
Timepoint [3] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [4] 0 0
The Mean Absolute Values of FSFI Domain Score (Arousal) at Baseline - Sum of questions 3 to 6 on sexual arousal on the FSFI Questionnaire at Baseline. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best).
Timepoint [4] 0 0
At Baseline
Secondary outcome [5] 0 0
The Mean Absolute Values of FSFI Domain Score (Arousal) at Cycle 6 - Sum of questions 3 to 6 on sexual arousal on FSFI Questionnaire at Cycle 6. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best).
Timepoint [5] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [6] 0 0
Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Arousal) - Mean change from Baseline to Cycle 6 in the sum of questions 3 to 6 on sexual arousal on the FSFI Questionnaire. The change in the normalized score for those 4 questions ranges from -6 (worst) to 6 (best).
Timepoint [6] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [7] 0 0
The Mean Absolute Values of FSFI Domain Score (Lubrication) at Baseline - Sum of questions 7 to 10 on lubrication on the FSFI Questionnaire at Baseline. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best).
Timepoint [7] 0 0
At Baseline
Secondary outcome [8] 0 0
The Mean Absolute Values of FSFI Domain Score (Lubrication) at Cycle 6 - Sum of questions 7 to 10 on lubrication on the FSFI Questionnaire at Cycle 6. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best).
Timepoint [8] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [9] 0 0
Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Lubrication) - Mean change from Baseline at Cycle 6 in the sum of questions 7 to 10 on the FSFI Questionnaire. The change in the normalized score for those 4 questions ranges from -6 (worst) to 6 (best).
Timepoint [9] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [10] 0 0
The Mean Absolute Values of FSFI Domain Score (Orgasm) at Baseline - Sum of questions 11 to 13 on orgasm on FSFI Questionnaire at Baseline. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best).
Timepoint [10] 0 0
At Baseline
Secondary outcome [11] 0 0
The Mean Absolute Values of FSFI Domain Score (Orgasm) at Cycle 6 - Sum of questions 11 to 13 on orgasm on the FSFI Questionnaire at Cycle 6. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best).
Timepoint [11] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [12] 0 0
Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Orgasm) - Mean change from Baseline to Cycle 6 in the sum of questions 11 to 13 on orgasm on the FSFI Questionnaire. The change in the normalized score for those 3 questions ranges from -6 (worst) to 6 (best).
Timepoint [12] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [13] 0 0
The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Baseline - Sum of Questions 14 to 16 on satisfaction on the FSFI Questionnaire at Baseline. The normalized score for those 3 questions ranges from 0.8 (worst) to 6 (best).
Timepoint [13] 0 0
At Baseline
Secondary outcome [14] 0 0
The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Cycle 6 - Sum of questions 14 to 16 on satisfaction on the FSFI Questionnaire at Cycle 6. The normalized score for those 3 questions ranges from 0.8 (worst) to 6 (best).
Timepoint [14] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [15] 0 0
Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Satisfaction) - Mean change from Baseline to Cycle 6 in the sum of questions 14 to 16 on satisfaction on the FSFI Questionnaire. The change in the normalized score for those 3 questions ranges from -5.2 (worst) to 5.2 (best).
Timepoint [15] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [16] 0 0
The Mean Absolute Values of FSFI Domain Score (Pain) at Baseline. - Sum of questions 17 to 19 on pain on the FSFI Questionnaire at Baseline. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best).
Timepoint [16] 0 0
At Baseline
Secondary outcome [17] 0 0
The Mean Absolute Values of FSFI Domain Score (Pain) at Cycle 6 - Sum of questions 17 to 19 on pain on the FSFI Questionnaire at Cycle 6. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best).
Timepoint [17] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [18] 0 0
Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Pain) - Mean change from Baseline to Cycle 6 in the sum of questions 17 to 19 on pain on the FSFI Questionnaire. The change in the normalized score for those 3 questions ranges from -6 (worst) to 6 (best).
Timepoint [18] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [19] 0 0
The Mean Absolute Values of FSFI Total Score at Baseline - The normalized FSFI total score was the weighted sum of the domain scores covering a range from 2 (worst) to 36 (best).
Timepoint [19] 0 0
At Baseline
Secondary outcome [20] 0 0
The Mean Absolute Values of FSFI Total Score at Cycle 6 - The normalized FSFI total score was the weighted sum of the domain scores covering a range from 2 (worst) to 36 (best).
Timepoint [20] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [21] 0 0
Mean Change From Baseline to Cycle 6 in FSFI Total Score - The change in the normalized FSFI total score ranges from -34 (worst) to 34 (best).
Timepoint [21] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [22] 0 0
The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Baseline - Validated, 13-item scale (0=never to 4=always) that assesses subjective distress associated with sexual dysfunction in women. A decrease in the total score=decrease in frequency of the subjective distress symptom. The total score ranges from 0 (worst) to 52 (best).
Timepoint [22] 0 0
At Baseline
Secondary outcome [23] 0 0
The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Cycle 6 - Validated, 13-item scale (0=never to 4=always) that assesses subjective distress associated with sexual dysfunction in women. A decrease in the total score=decrease in frequency of the subjective distress symptom. The total score ranges from 0 (worst) to 52 (best).
Timepoint [23] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [24] 0 0
Mean Change From Baseline to Cycle 6 in Female Sexual Distress Scale (FSDS-R) Total Score - Change from Baseline to Cycle 6 in the validated, 13-item scale (0=never to 4=always) that assesses subjective distress associated with sexual dysfunction in women. A decrease in the total score=decrease in frequency of the subjective distress symptom. The change in total score ranges from -52 (best) to 52 (worst).
Timepoint [24] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [25] 0 0
The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Baseline - Q-LES-Q (short version - 16 items) assessed at Baseline the degree of enjoyment and satisfaction during the past week taking everything into consideration on a 1-5 scale (very poor, poor, fair, good, very good). The normalized score ranges from 0 (worst) to 100 (best).
Timepoint [25] 0 0
At Baseline
Secondary outcome [26] 0 0
The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Cycle 6 - Q-LES-Q (short version - 16 items) assessed at Cycle 6 the degree of enjoyment and satisfaction during the past week taking everything into consideration on a 1-5 scale (very poor, poor, fair, good, very good). The normalized score ranges from 0 (worst) to 100 (best).
Timepoint [26] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [27] 0 0
Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score - Change from Baseline to Cycle 6 in the overall enjoyment and satisfaction experienced during the past week as scored on the QLES-Q (short version - 16 items). 1-5 scale (very poor, poor, fair, good, very good). The normalized score ranges from 0 (worst) to 100 (best). The change in the normalized score ranges from -100 (worst) to 100 (best).
Timepoint [27] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [28] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Baseline - The PGWBI measured at Baseline self-representations over the past 4 weeks of intrapersonal affective or emotional states reflecting a sense of subjective well-being or distress. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the well-being of the participant
Timepoint [28] 0 0
At Baseline
Secondary outcome [29] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Cycle 6 - The PGWBI measured at Cycle 6 self-representations over the past 4 weeks of intrapersonal affective or emotional states reflecting a sense of subjective well-being or distress. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the well-being of the participant
Timepoint [29] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [30] 0 0
Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) Global Score - Change from Baseline to Cycle 6 in the PGWBI Questionnaire's assessment of the participant's overall sense of well-being or distress. The response format used a 6-grade Likert scale and the change in the normalized PGWBI global score ranges from -100 (worst) to 100 (best).
Timepoint [30] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [31] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Baseline - Anxiety is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [31] 0 0
At Baseline
Secondary outcome [32] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Cycle 6 - Anxiety is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [32] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [33] 0 0
Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Anxiety - Anxiety is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - Anxiety score ranges from -100 (worst) to 100 (best).
Timepoint [33] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [34] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Baseline - Depressed mood is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [34] 0 0
At Baseline
Secondary outcome [35] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Cycle 6 - Depressed mood is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [35] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [36] 0 0
Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Depressed Mood - Depressed mood is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - depressed mood score ranges from -100 (worst) to 100 (best).
Timepoint [36] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [37] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Baseline - Positive well-being is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [37] 0 0
At Baseline
Secondary outcome [38] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Cycle 6 - Positive well-being is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [38] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [39] 0 0
Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Positive Well-being - Positive well-being is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - positive well-being score ranges from -100 (worst) to 100 (best).
Timepoint [39] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [40] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Baseline - Self-control is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [40] 0 0
At Baseline
Secondary outcome [41] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Cycle 6 - Self-control is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [41] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [42] 0 0
Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Self-control - Self-control is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - self-control score ranges from -100 (worst) to 100 (best).
Timepoint [42] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [43] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Baseline - General health is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [43] 0 0
At Baseline
Secondary outcome [44] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Cycle 6 - General health is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [44] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [45] 0 0
Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - General Health - General health is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale the change in the normalized PGWBI general health score ranges from -100 (worst) to 100 (best).
Timepoint [45] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [46] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Baseline - Vitality is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [46] 0 0
At Baseline
Secondary outcome [47] 0 0
The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Cycle 6 - Vitality is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.
Timepoint [47] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [48] 0 0
Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Vitality - Vitality is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - vitality score ranges from -100 (worst) to 100 (best).
Timepoint [48] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [49] 0 0
Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 6 - CGI is used to collect information regarding the subject's total clinical experience. The assessment scale ranges from 0 to 7: (0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse). The scale of 1, 2, and 3 were categorized as improvement.
Timepoint [49] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [50] 0 0
Percentage of Participants With Improvement in Participant's Assessment in Clinical Global Impression (CGI) at Cycle 6 - In 1 section of the CGI the subject rates their total improvement and rate of satisfaction with sexuality during treatment. The assessment scale ranges from 0 to 7: (0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse). The scale of 1, 2, and 3 were categorized as improvement.
Timepoint [50] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [51] 0 0
Vaginal Effects Evaluated by Vaginal pH at Cycle 6 - Vaginal pH (0 to 6) measured by subject using a pH indicator dipstick
Timepoint [51] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [52] 0 0
Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Baseline - ASQ consists of 5 items which define the status of the vagina. The response format uses a 4-point scale from 0 (none) to 3 (severe).
Timepoint [52] 0 0
At Baseline
Secondary outcome [53] 0 0
Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Cycle 6 - ASQ consists of 5 items which define the status of the vagina. The response format uses a 4-point scale from 0 (none) to 3 (severe).
Timepoint [53] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [54] 0 0
Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Atrophy Symptom Questionnaire (ASQ) - ASQ consists of 5 items which define the status of the vagina. The response format uses a 4-point scale from 0 (none) to 3 (severe). The change in average score ranges from -3 (best) to 3 (worst).
Timepoint [54] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [55] 0 0
Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Baseline - The VHA, performed by the Investigator during gynecological exam, is the average of 5 individual scores related to composition and appearance of the vagina (secretions, epithelial integrity, epithelial surface thickness, color, and pH) scored from 0 (no atrophy or pH<4) to 3 (severe or pH5).
Timepoint [55] 0 0
At Baseline
Secondary outcome [56] 0 0
Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Cycle 6 - The VHA, performed by the Investigator during gynecological exam, is the average of 5 individual scores related to composition and appearance of the vagina (secretions, epithelial integrity, epithelial surface thickness, color, and pH) scored from 0 (no atrophy or pH<4) to 3 (severe or pH5).
Timepoint [56] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [57] 0 0
Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Vaginal Health Assessment (VHA) - The VHA, performed by the Investigator during gynecological exam, is the average of 5 individual scores related to composition and appearance of the vagina (secretions, epithelial integrity, epithelial surface thickness, color, and pH) scored from 0 (no atrophy or pH<4) to 3 (severe or pH5). The change in average score ranges from -3 (best) to 3 (worst).
Timepoint [57] 0 0
Baseline up to Cycle 6 (28 days per Cycle)
Secondary outcome [58] 0 0
Number of Bleeding / Spotting Days in Reference Period 1 - Reference Period 1 is defined as Day 1 to 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.
Timepoint [58] 0 0
From Day 1 to Day 90
Secondary outcome [59] 0 0
Number of Bleeding / Spotting Days in Reference Period 2 - Reference Period 2 is defined as Day 91 to 180 during study treatment
Timepoint [59] 0 0
From Day 91 to Day 180
Secondary outcome [60] 0 0
Number of Bleeding / Spotting Episodes in Reference Period 1 - Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the fist treatment cycle includes 2 bleeding episodes
Timepoint [60] 0 0
From Day 1 to Day 90
Secondary outcome [61] 0 0
Number of Bleeding / Spotting Episodes in Reference Period 2 - Reference Period 2 is defined as Day 91 to Day 180 during study treatment
Timepoint [61] 0 0
From Day 91 to Day 180
Secondary outcome [62] 0 0
Mean Length of Bleeding / Spotting Episodes in Reference Period 1 - Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes
Timepoint [62] 0 0
From Day 1 to Day 90
Secondary outcome [63] 0 0
Mean Length of Bleeding / Spotting Episodes in Reference Period 2 - Reference Period 2 is defined as Day 91 to Day 180 during study treatment.
Timepoint [63] 0 0
From Day 91 to Day 180
Secondary outcome [64] 0 0
Maximum Length of Bleeding / Spotting Episodes in Reference Period 1 - Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.
Timepoint [64] 0 0
From Day 1 to Day 90
Secondary outcome [65] 0 0
Maximum Length of Bleeding / Spotting Episodes in Reference Period 2 - Reference Period 2 is defined as Day 91 to Day 180 during study treatment.
Timepoint [65] 0 0
From Day 91 to Day 180
Secondary outcome [66] 0 0
Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 1 - Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.
Timepoint [66] 0 0
From Day 1 to Day 90
Secondary outcome [67] 0 0
Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 2 - Reference Period 2 is defined as Day 91 to Day 180 during study treatment.
Timepoint [67] 0 0
From Day 91 to Day 180
Secondary outcome [68] 0 0
Number of Spotting Only Days in Reference Period 1 - Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.
Timepoint [68] 0 0
From Day 1 to Day 90
Secondary outcome [69] 0 0
Number of Spotting Only Days in Reference Period 2 - Reference Period 2 is defined as Day 91 to Day 180 during study treatment.
Timepoint [69] 0 0
From Day 91 to Day 180
Secondary outcome [70] 0 0
Number of Spotting Only Episodes in Reference Period 1 - Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.
Timepoint [70] 0 0
From Day 1 to Day 90
Secondary outcome [71] 0 0
Number of Spotting Only Episodes in Reference Period 2 - Reference Period 2 is defined as Day 91 to Day 180 during study treatment.
Timepoint [71] 0 0
From Day 91 to Day 180
Secondary outcome [72] 0 0
Mean Length of Spotting-only Episodes in Reference Period 1 - Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.
Timepoint [72] 0 0
From Day 1 to Day 90
Secondary outcome [73] 0 0
Mean Length of Spotting-only Episodes in Reference Period 2 - Reference Period 2 is defined as Day 91 to Day 180 during study treatment.
Timepoint [73] 0 0
From Day 91 to Day 180
Secondary outcome [74] 0 0
Maximum Length of Spotting-only Episodes in Reference Period 1 - Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.
Timepoint [74] 0 0
From Day 1 to Day 90
Secondary outcome [75] 0 0
Maximum Length of Spotting-only Episodes in Reference Period 2 - Reference Period 2 is defined as Day 91 to Day 180 during study treatment.
Timepoint [75] 0 0
From Day 91 to Day 180
Secondary outcome [76] 0 0
Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 1 - Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.
Timepoint [76] 0 0
From Day 1 to Day 90
Secondary outcome [77] 0 0
Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 2 - Reference Period 2 is defined as Day 91 to Day 180 during study treatment.
Timepoint [77] 0 0
From Day 91 to Day 180
Secondary outcome [78] 0 0
Percentage of Participants With / Without Withdrawal Bleeding at Cycle 1 - Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end
Timepoint [78] 0 0
At Cycle 1 (28 days per Cycle)
Secondary outcome [79] 0 0
Percentage of Participants With / Without Withdrawal Bleeding at Cycle 3 - Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end
Timepoint [79] 0 0
At Cycle 3 (28 days per Cycle)
Secondary outcome [80] 0 0
Percentage of Participants With / Without Withdrawal Bleeding at Cycle 6 - Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end
Timepoint [80] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [81] 0 0
Length of Withdrawal Bleeding Episodes at Cycle 1 - Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end
Timepoint [81] 0 0
At Cycle 1 (28 days per Cycle)
Secondary outcome [82] 0 0
Length of Withdrawal Bleeding Episodes at Cycle 3 - Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end
Timepoint [82] 0 0
At Cycle 3 (28 days per Cycle)
Secondary outcome [83] 0 0
Length of Withdrawal Bleeding Episodes at Cycle 6 - Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end
Timepoint [83] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [84] 0 0
Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1 - Intensity was rated as 1=spotting; 2=light; 3=normal or 4=heavy.
Timepoint [84] 0 0
At Cycle 1 (28 days per Cycle)
Secondary outcome [85] 0 0
Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3 - Intensity was rated as 1=spotting; 2=light; 3=normal or 4=heavy.
Timepoint [85] 0 0
At Cycle 3 (28 days per Cycle)
Secondary outcome [86] 0 0
Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6 - Intensity was rated as 1=spotting; 2=light; 3=normal or 4=heavy.
Timepoint [86] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [87] 0 0
Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1 - Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end. Intensity rated on 4-point scale from 1=spotting to 4=heavy.
Timepoint [87] 0 0
At Cycle 1 (28 days per Cycle)
Secondary outcome [88] 0 0
Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3 - Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end. Intensity rated on 4-point scale from 1=spotting to 4=heavy.
Timepoint [88] 0 0
At Cycle 3 (28 days per Cycle)
Secondary outcome [89] 0 0
Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6 - Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end. Intensity rated on 4-point scale from 1=spotting to 4=heavy.
Timepoint [89] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [90] 0 0
Onset of Withdrawal Bleeding Episodes at Cycle 1 - Onset of withdrawal bleeding was calculated from the end of the exposure to the progestogen component (Day 24 for EV/DNG and Day 21 for EE/LNG). Therefore the count for the onset started at each Cycle on Day 25 for EV/DNG and Day 22 for EE/LNG.
Timepoint [90] 0 0
From Day 24 for EV/DNG and Day 21 for EE/LNG to Day 28 for Cycle 1
Secondary outcome [91] 0 0
Onset of Withdrawal Bleeding Episodes at Cycle 3 - Onset of withdrawal bleeding was calculated from the end of the exposure to the progestogen component (Day 24 for EV/DNG and Day 21 for EE/LNG). Therefore the count for the onset started at each Cycle on Day 25 for EV/DNG and Day 22 for EE/LNG.
Timepoint [91] 0 0
From Day 24 for EV/DNG and Day 21 for EE/LNG to Day 28 for Cycle 3
Secondary outcome [92] 0 0
Onset of Withdrawal Bleeding Episodes at Cycle 6 - Onset of withdrawal bleeding was calculated from the end of the exposure to the progestogen component (Day 24 for EV/DNG and Day 21 for EE/LNG). Therefore the count for the onset started at each Cycle on Day 25 for EV/DNG and Day 22 for EE/LNG.
Timepoint [92] 0 0
From Day 24 for EV/DNG and Day 21 for EE/LNG to Day 28 for Cycle 6
Secondary outcome [93] 0 0
Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 1 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [93] 0 0
At Cycle 1 (28 days per Cycle)
Secondary outcome [94] 0 0
Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 3 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [94] 0 0
At Cycle 3 (28 days per Cycle)
Secondary outcome [95] 0 0
Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 6 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [95] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [96] 0 0
Number of Intracyclic Bleeding Episodes at Cycle 1 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [96] 0 0
At Cycle 1 (28 days per Cycle)
Secondary outcome [97] 0 0
Number of Intracyclic Bleeding Episodes at Cycle 3 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [97] 0 0
At Cycle 3 (28 days per Cycle)
Secondary outcome [98] 0 0
Number of Intracyclic Bleeding Episodes at Cycle 6 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [98] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [99] 0 0
Maximum Length of Intracyclic Bleeding Episodes at Cycle 1 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [99] 0 0
At Cycle 1 (28 days per Cycle)
Secondary outcome [100] 0 0
Maximum Length of Intracyclic Bleeding Episodes at Cycle 3 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [100] 0 0
At Cycle 3 (28 days per Cycle)
Secondary outcome [101] 0 0
Maximum Length of Intracyclic Bleeding Episodes at Cycle 6 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [101] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [102] 0 0
Number of Intracyclic Bleeding Days at Cycle 1 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [102] 0 0
At Cycle 1 (28 days per Cycle)
Secondary outcome [103] 0 0
Number of Intracyclic Bleeding Days at Cycle 3 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [103] 0 0
At Cycle 3 (28 days per Cycle)
Secondary outcome [104] 0 0
Number of Intracyclic Bleeding Days at Cycle 6 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [104] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [105] 0 0
Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. Intensity rated on 4-point scale where 1=spotting; 2=light; 3=normal; and 4=heavy.
Timepoint [105] 0 0
At Cycle 1 (28 days per Cycle)
Secondary outcome [106] 0 0
Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. Intensity rated on 4-point scale where 1=spotting; 2=light; 3=normal; and 4=heavy.
Timepoint [106] 0 0
At Cycle 3 (28 days per Cycle)
Secondary outcome [107] 0 0
Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 6 - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. Intensity rated on 4-point scale where 1=spotting; 2=light; 3=normal; and 4=heavy.
Timepoint [107] 0 0
At Cycle 6 (28 days per Cycle)
Secondary outcome [108] 0 0
Percentage of Participants With at Least 1 Intracyclic Bleeding Episode - Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.
Timepoint [108] 0 0
Up to Cycle 6 (28 days per Cycle)

Eligibility
Key inclusion criteria
- OC-associated female sexual dysfunction (FSD) for at least 3 months but no longer than
one year and willingness to continue OC use but to switch to SH T00658ID or Microgynon

- Combined score of the sexual desire and arousal domains of the FSFI questionnaire of
18 or below at screening and baseline
Minimum age
18 Years
Maximum age
50 Years
Gender
Females
Can healthy volunteers participate?
No
Key exclusion criteria
- Contraindications for oral contraceptive use, for example but not limited to: presence
or history of venous or arterial thrombotic / thromboembolic events, hypertension,
presence or history of severe hepatic disease

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Sydney Centre for Reproductive Health Reseach - Ashfield
Recruitment hospital [2] 0 0
Royal Hospital for Women - Sydney
Recruitment hospital [3] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [4] 0 0
The Alfred Hospital - Prahran
Recruitment hospital [5] 0 0
Queen Elizabeth II Medical Centre - Nedlands
Recruitment hospital [6] 0 0
King Edward Memorial Hospital - Subiaco
Recruitment postcode(s) [1] 0 0
2031 - Ashfield
Recruitment postcode(s) [2] 0 0
2031 - Sydney
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3121 - Prahran
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment postcode(s) [6] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Niederösterreich
Country [2] 0 0
Austria
State/province [2] 0 0
Steiermark
Country [3] 0 0
Austria
State/province [3] 0 0
Wien
Country [4] 0 0
Austria
State/province [4] 0 0
Zeltweg
Country [5] 0 0
Belgium
State/province [5] 0 0
Bruxelles - Brussel
Country [6] 0 0
Belgium
State/province [6] 0 0
Gent
Country [7] 0 0
Belgium
State/province [7] 0 0
Leuven
Country [8] 0 0
Germany
State/province [8] 0 0
Baden-Württemberg
Country [9] 0 0
Germany
State/province [9] 0 0
Nordrhein-Westfalen
Country [10] 0 0
Germany
State/province [10] 0 0
Sachsen
Country [11] 0 0
Germany
State/province [11] 0 0
Hamburg
Country [12] 0 0
Italy
State/province [12] 0 0
Cagliari
Country [13] 0 0
Italy
State/province [13] 0 0
Catania
Country [14] 0 0
Italy
State/province [14] 0 0
Pavia
Country [15] 0 0
Italy
State/province [15] 0 0
Pisa
Country [16] 0 0
Spain
State/province [16] 0 0
Barcelona
Country [17] 0 0
Spain
State/province [17] 0 0
Alicante
Country [18] 0 0
Spain
State/province [18] 0 0
Granada
Country [19] 0 0
Spain
State/province [19] 0 0
Madrid
Country [20] 0 0
Thailand
State/province [20] 0 0
Bangkok

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The aim of the study is to investigate whether women on oral contraceptives (OCs) suffering
from acquired OC-associated female sexual dysfunction (FSD) for at least 3 months but no
longer than one year will express the same level of sexual distress when taking SH T00658ID
compared to Microgynon, the usual OC prescribed for women with OC-associated FSD.
Trial website
https://clinicaltrials.gov/show/NCT00764881
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications